Literature DB >> 34107980

Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection.

Haoda Chen1, Fanlu Li1, Siyi Zou1, Junjie Xie1, Jun Zhang1, Xiaxing Deng1, Hao Chen2, Baiyong Shen3.   

Abstract

BACKGROUND: Elevated plasma D-dimer levels have been reported as an unfavorable prognostic indicator in many solid tumors. However, there are limited relevant studies in pancreatic cancer patients following radical surgery, and the clinical significance remains controversial. The aim of this study was to investigate the clinical and prognostic significance of preoperative plasma D-dimer in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing resection.
METHODS: A retrospective analysis was performed on all patients who consecutively underwent radical surgery for PDAC by laparotomy or robotic surgery from December 2011 to December 2018. Baseline clinicopathologic characteristics, preoperative laboratory parameters, and follow-up information were collected. Univariate and multivariate analyses were performed to analyze the prognostic value of preoperative plasma D-dimer.
RESULTS: Among 1351 patients, elevated preoperative plasma D-dimer levels (≥ 0.55 ng/mL) were found in 417 (30.9%) patients. Three hundred twelve (23.09%) underwent minimally invasive robotic pancreatectomy. The median overall survival (OS) of patients with elevated D-dimer levels was 6.3 months shorter than that of patients with normal D-dimer levels (15.0 months vs 21.3 months, p < 0.001). Multivariate analysis showed that elevated D-dimer levels independently predicted poorer OS (hazard ratio, 1.33; 95% confidence interval, 1.17-1.51, p < 0.001). Subgroup analysis demonstrated that D-dimer was a reliable prognostic factor in patients who underwent R0 resection. In addition, integration of D-dimer, carbohydrate antigen 19-9 (CA19-9), and NLR provided a better prognostic model for PDAC patients before operation.
CONCLUSION: An elevated preoperative plasma D-dimer level was a reliable independent prognostic factor for OS in patients with PDAC undergoing resection. Combination of D-dimer, CA19-9, and NLR can enhance the prognostic accuracy before operation.

Entities:  

Keywords:  D-dimer; Pancreatic ductal adenocarcinoma (PDAC); Pancreatic surgery; Prognostic factors

Mesh:

Substances:

Year:  2021        PMID: 34107980     DOI: 10.1186/s12957-021-02281-8

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  40 in total

1.  CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection.

Authors:  Jiarui Li; Zhe Li; Haoxuan Kan; Zhao Sun; Jiazhang Xing; Yuejuan Cheng; Chunmei Bai
Journal:  Pancreatology       Date:  2019-02-01       Impact factor: 3.996

2.  A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.

Authors:  Liang Liu; Huaxiang Xu; Wenquan Wang; Chuntao Wu; Yong Chen; Jingxuan Yang; Putao Cen; Jin Xu; Chen Liu; Jiang Long; Sushovan Guha; Deliang Fu; Quanxing Ni; Aminah Jatoi; Suresh Chari; Angela L McCleary-Wheeler; Martin E Fernandez-Zapico; Min Li; Xianjun Yu
Journal:  Int J Cancer       Date:  2014-10-18       Impact factor: 7.396

Review 3.  Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview.

Authors:  S Bünger; T Laubert; U J Roblick; J K Habermann
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-31       Impact factor: 4.553

Review 4.  Pancreatic cancer and thromboembolic disease.

Authors:  Alok A Khorana; Robert L Fine
Journal:  Lancet Oncol       Date:  2004-11       Impact factor: 41.316

Review 5.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

6.  Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type.

Authors:  P M Pour; M M Tempero; H Takasaki; E Uchida; Y Takiyama; D A Burnett; Z Steplewski
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

7.  The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.

Authors:  Mohammad Hosein Aziz; Kostandinos Sideras; Nasir Ahmad Aziz; Katya Mauff; Roel Haen; Daphne Roos; Lawlaw Saida; Mustafa Suker; Erwin van der Harst; Jan Sven Mieog; Bert A Bonsing; Yarne Klaver; Bas Groot Koerkamp; Casper H van Eijck
Journal:  Ann Surg       Date:  2019-07       Impact factor: 12.969

Review 8.  Pancreatic cancer.

Authors:  Terumi Kamisawa; Laura D Wood; Takao Itoi; Kyoichi Takaori
Journal:  Lancet       Date:  2016-01-30       Impact factor: 79.321

9.  Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.

Authors:  Susan Tsai; Ben George; David Wittmann; Paul S Ritch; Ashley N Krepline; Mohammed Aldakkak; Chad A Barnes; Kathleen K Christians; Kulwinder Dua; Michael Griffin; Catherine Hagen; William A Hall; Beth A Erickson; Douglas B Evans
Journal:  Ann Surg       Date:  2020-04       Impact factor: 12.969

10.  Frailty is a useful predictive marker of postoperative complications after pancreaticoduodenectomy.

Authors:  Yutaka Nakano; Yuki Hirata; Tatsuya Shimogawara; Toru Yamada; Koki Mihara; Ryo Nishiyama; Shin Nishiya; Hideki Taniguchi; Tomohisa Egawa
Journal:  World J Surg Oncol       Date:  2020-08-03       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.